METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody combo aims to boost lung cancer treatment response
Disease control Recruiting nowThis study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than placebo in people with newly diagnosed metastatic non-squamous non-small cell lung cancer. About 107 adults who have not had prior treatment f…
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated May 26, 2026 07:19 UTC
-
New drug cocktail aims to shrink lung tumors when standard care fails
Disease control Recruiting nowThis study tests a new drug called visugromab combined with nivolumab and/or docetaxel in people with advanced non-squamous lung cancer that has worsened after initial treatment. About 131 participants will receive different combinations to see if the new mix shrinks tumors bette…
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Virus therapy takes on lung cancer after standard treatment fails
Disease control Recruiting nowThis study tests a new approach for people with advanced non-small-cell lung cancer whose disease has worsened after initial chemotherapy and immunotherapy. Participants receive an experimental virus (Olvi-Vec) followed by chemotherapy plus an immunotherapy drug, or the standard …
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated May 22, 2026 14:02 UTC